[2021-05-03] Miss our webinar on the value of patient preferences? Video now available! - PREFER

Miss our webinar on the value of patient preferences? Video now available!

On 26 April, the PREFER project organised the first in a series of webinars presenting and discussing results from the project. Want to know what a patient preference is? And how preferences are different from patient reported outcomes? You can now watch a recording of the presentations. The presentations covers the actors that make decisions throughout the medicinal product life cycle, and how they can benefit from patient preference studies. We also explain what we mean by patient preference sensitive situations.

You can watch the full hour on YouTube, or divide the webinar into parts.

What are patient preferences

In this presentation, Isabelle Huys from KU Leuven, sets the scene for presentations the value of patient preference studies for different stakeholders. Her presentation covers what patient preferences are, the difference between Patient Reported Outcomes (PROs) and patient preferences, and who stands to benefit from patient preference studies. She also explains what we mean by patient preference sensitive situations.

YouTube

Value of patient preferences in regulatory decision-making

In this presentation, Mireille Mueller from Novartis and Monika Brand from JNJ explains the role that patient preference input can have have in regulatory decision making.

YouTube

Value of patient preferences in HTA/payer decision-making

In this presentation, Irina Cleemput from the Belgian HTA authority KCE talks about the value in decision making by health technology assessors and payers.

YouTube

Stakeholders´ needs towards patient preference studies

In this presentation, Rosanne Janssens from KU Leuven presents the stakeholder needs that can be met by using patient preference studies across the medical product life cycle.

YouTube

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).